Further Amendment to Duties Addressing the Synthetic Opioid Supply Chain in the People's Republic of China as Applied to Low-Value Imports

On April 2, 2025, President Donald Trump issued an executive order amending duties on low-value imports from China and Hong Kong to combat the synthetic opioid crisis in the United States. This order eliminates duty-free treatment for certain imports, applying new duties to shipments valued at or under $800, effective May 2, 2025. The move aims to curb the influx of synthetic opioids, with potential legal and political implications as it challenges trade norms and may impact U.S.-China relations.